Abstract: Inflammatory rheumatic diseases (IRD) patients have the same risk factors for severe COVID-19 regarding comorbidities compared to the general population without any immune-mediated disease or immunomodulation. The use of rituximab was associated with an increased risk for severe COVID-19. On the other hand, the use of TNF-I was associated with less severe COVID-19 compared to the general population, which might indicate a protective effect of TNF-I against severe COVID-19 disease.
Introduction
Early in the COVID-19 pandemic, there was significant concern that patients with inflammatory rheumatic diseases (IRD)—such as rheumatoid arthritis or lupus—were at a much higher risk for severe illness and death. These patients often have overactive immune systems and take immunosuppressive drugs, leading to the logical assumption that they would be more vulnerable to SARS-CoV-2.
However, the relationship between immunomodulation and COVID-19 is complex. Since severe COVID-19 is often driven by a "cytokine storm" (an out-of-control inflammatory response), researchers hypothesized that the very drugs used to treat rheumatism might actually mitigate the most dangerous stages of the infection. This study compares COVID-19 outcomes between IRD patients and the general population using two major German registries to clarify how specific rheumatic treatments influence disease severity.
Methodology and Data Sources
The researchers conducted a retrospective cohort study using data from two distinct sources:
- The German COVID-19 IRD Registry: A nationwide registry where rheumatologists enter data on IRD patients infected with SARS-CoV-2.
- The LEOSS Registry (Lean European Survey on SARS-CoV-2): A multi-center registry collecting clinical data on the general population infected with COVID-19 across Germany and Europe.
To ensure a fair "apples-to-apples" comparison, the team employed a 1:1 matching strategy, pairing 366 inpatients from the IRD registry with 366 inpatients from the LEOSS registry based on age and gender. Disease severity was analyzed using ordinal logistic regression on a three-level scale: hospitalization, oxygen administration/non-invasive ventilation, and invasive ventilation/death.
Key Findings: The Impact of Immunomodulation
The study revealed that when matched for age and gender, IRD patients did not show a significantly higher lethality rate compared to the general population (16.9% in IRD vs. 15.0% in the general population). Standard risk factors like age over 65, diabetes, and COPD remained the primary drivers of severity in both groups.
However, specific treatments showed divergent effects:
- The TNF-I Shield: The most striking finding was the protective role of TNF-alpha inhibitors. The use of these drugs was associated with a 50% reduction in the odds of severe disease (OR 0.5; 95% CI 0.2 to 0.9). By blocking TNF-alpha, a pro-inflammatory signaling protein, these drugs may prevent the hyper-inflammation that leads to lung failure.
- Rituximab Risk: Conversely, the drug rituximab (which depletes B-cells) was associated with significantly worse outcomes, with an odds ratio of 2.5 (95% CI 1.4 to 4.7).
Discussion and Limitations
The findings highlight that "immunosuppression" is not a monolith; the specific pathway being blocked matters immensely during a viral challenge. While TNF-I appears protective, B-cell depletion via rituximab increases vulnerability.
The authors acknowledge several limitations, including the lack of vaccination data (as the study covers the first two waves up to January 2021) and potential selection bias inherent in voluntary registries. Furthermore, the study predates the emergence of Delta and Omicron variants. Future research is needed to determine if these protective effects hold true against current variants and how they interact with hybrid immunity from both vaccination and prior infection.
Summary updated